Cancer Immunotherapeutics In the News
In the three decades since robots first entered the operating room, these increasingly sophisticated machines have helped surgeons perform more than a million procedures, all over the human body.
What's it like to work at the center of a true medical and scientific revolution? It's emotional, often overwhelming. But it’s also a place to witness miracles. Such is the life of the clinical research nurses who staff City of Hope's CAR T cell program.
Meet float rider Cheryl Wiers, a wife and mother of two who battled cancer twice only to have it return. She eventually found prolonged remission thanks to a CAR T Cell therapy offered at City of Hope.
City of Hope clinical and laboratory investigators presented leading-edge research, including new targets in CAR T cell therapy, at the 60th annual ASH meeting in San Diego.
Xiuli Wang, Ph.D., research professor at City of Hope, presented encouraging research on using CAR T cell therapy for central nervous system lymphoma at this year's American Society of Hematology conference.
Physicians and researchers at the 2018 American Society of Hematology conference presented clinical trials for new leukemia and lymphoma treatments, laying the groundwork for innovative therapeutic approaches aimed at improving treatment options and quality of life for patients.
City of Hope physicians and researchers at the American Society of Hematology (ASH) meeting in San Diego presented clinical trials for novel leukemia and lymphoma treatments that could improve outcomes for patients.
CAR T cell therapy is one of the most promising new approaches for treating cancer today. Come spend a day learning more about CAR T cell therapy from City of Hope’s resident experts to better understand what is now at the forefront of oncology treatment.
City of Hope announced today that it will present data on new findings on immunotherapies, including CAR T cell therapy, bone marrow transplants and other treatments for blood cancers, at the American Society of Hematology (ASH) Annual Meeting Dec. 1-4 in San Diego.
City of Hope, TGen announce letter of intent to build cell therapy manufacturing facility in Phoenix. The move would enable the organizations to meet a demand for clinical cell therapies that is expected to grow 42 percent annually over the next decade.
City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.
A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants.
Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge. The immunotherapy trial is the first to deliver CAR T cells directly to the brain of HER2-positive breast cancer patients with brain metastases.
Harnessing the power of CAR T cells
The scientists developed a synthetic DNA molecule that disables tumor defense systems while inducing immune responses – a two-step immunotherapy that eliminated difficult-to-treat prostate cancer in experimental models
The California Institute for Regenerative Medicine today awarded City of Hope’s Xiuli Wang, Ph.D., $3.8 million to develop CAR T cells that can target and kill HIV-infected cells. The treatment will also use the cytomegalovirus vaccine to stimulate the immune system to proliferate and maintain the CAR T cells.
The California Institute for Regenerative Medicine has awarded City of Hope’s Xiuli Wang, Ph.D., $3.8 million to develop chimeric antigen receptor (CAR) T cells that can target and kill HIV-infected cells.
City of Hope’s Stephen J. Forman, M.D., is now an official member of the Parker Institute for Cancer Immunotherapy.
Since 2013, City of Hope researcher Saul Priceman, Ph.D., and his team have developed one of most comprehensive CAR T programs in the nation.
City of Hope's Linda Malkas, Ph.D., never envisioned a life in cancer research for herself. She wanted to be an astronaut, but after attending engineering school, she abandoned her interest in going into space.
Susanne Gray Warner, M.D., a surgical oncologist at City of Hope, on what you need to know regarding pancreatic cancer.
Skin cancer is the most common kind of cancer. It takes many forms, but even melanoma, the rarest and most aggressive form, has a nearly 100 percent cure rate. City of Hope's Kim Margolin, M.D., discusses melanoma diagnosis and treatment.
These three City of Hope physicians have dramatically different backgrounds, but they share a devotion to helping people and saving lives and now they share in the generosity of longtime City of Hope philanthropists Norman and Melinda Payson. Vijay Trisal, M.D., Jeffrey Weitzel, M.D., and John Chan, M.D., were recent invested through gifts made from the Payson family.
After many complications, City of Hope lymphoma patient Lucy found renewed hope after an immunotherapy clinical trial.
City of Hope’s CAR T research and treatment team is now an official member of the Parker Institute for Cancer Immunotherapy.